The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Bearish -55

Why The Cooper Companies, Inc. (COO) Crashed On Friday

Analyst downgrade Guidance lowered AI-generated analysis

πŸ“‰ COO shares dropped 14.61% on Friday, extending a three-day losing streak to close at $68.28.

πŸ“‰ The company lowered its FY2025 organic growth guidance to 5-6%, down from the prior target of 6-8%.

πŸ“‰ JPMorgan downgraded COO to 'neutral' with a new price target of $76, reduced from $110.

πŸ“‰ Wells Fargo cut its price target for The Cooper Companies from $118 to $93 following the weak outlook.

⚠️ Analysts cited mixed execution over several quarters and potential market trend slowdowns as key concerns.

Risk Factors
  • Shares fell 14.61% on Friday, marking a third consecutive day of declines driven by weak investor sentiment.
  • The company reduced its FY2025 organic growth guidance to 5-6%, missing the previously targeted range of 6-8%.
  • JPMorgan downgraded the stock from 'overweight' to 'neutral' and slashed its price target from $110 to $76.
  • Wells Fargo lowered its price target for COO from $118 to $93 following the earnings announcement.
Full Analysis
The Cooper Companies, Inc. (NASDAQ:COO) shares tumbled 14.61% on Friday, marking a third consecutive day of declines as investors reacted negatively to the company's lowered guidance for fiscal year 2025. Management revised its organic growth outlook down to a range of 5% to 6%, missing the previously targeted 6% to 8% expansion rate. Following the earnings announcement, major Wall Street analysts reduced their bullish stance on the medical device manufacturer. JPMorgan cut its rating from 'overweight' to 'neutral' and lowered its price target significantly from $110 to $76, citing mixed execution over recent quarters and concerns about a potential durable slowdown in market trends. Wells Fargo also participated in the sell-off by reducing its price target for COO from $118 to $93. The consensus among analysts suggests that the company faces headwinds related to its core business performance, leading to a broader reassessment of its valuation and future growth prospects despite its position in the medical device sector.